Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aquaporins01:25

Aquaporins

5.7K
Aquaporins or AQPs are a family of integral membrane proteins whose primary function is to transport water, while some called aquaglyceroporins also transport glycerol. In addition, aquaporins have also been suspected to be involved in transporting volatile substances, such as carbon dioxide and ammonia, across membranes. Such AQPs that act as gas channels are often highly expressed in cells involved in the gaseous exchange, such as red blood cells, epithelial cells, and pulmonary capillaries.
5.7K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

819
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
819
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study.

Lupus science & medicine·2026
Same author

Purified zymogens reveal mechanisms of snake venom metalloproteinase auto-activation.

eLife·2026
Same author

Factor V Leiden (R506Q), Prothrombin G20210A, and MTHFR C677T Variants and Thrombophilia in Qatar Biobank Participants: A Case Control Study.

Pathophysiology : the official journal of the International Society for Pathophysiology·2024
Same author

Platelet generation in vivo and in vitro.

Blood·2024
Same author

Platelets tell old red cells to clear off.

Blood·2024
Same author

Membrane procoagulation and N‑terminomics/TAILS profiling in Montreal platelet syndrome kindred with VWF p.V1316M mutation.

Communications medicine·2023

Related Experiment Video

Updated: Nov 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

Aquaporins in platelet function.

Ejaife O Agbani1, Alastair W Poole2

  • 1Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Alberta, Canada.

Platelets
|April 5, 2021
PubMed
Summary

Aquaporins (AQPs) facilitate water transport in platelets, influencing blood clotting. Targeting AQPs offers a novel approach for developing anti-thrombotic therapies distinct from current treatments.

Keywords:
AquaporinHaemostasisPlateletsProcoagulant Membrane DynamicsThrombosis

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.9K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.2K

Related Experiment Videos

Last Updated: Nov 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.9K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.2K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Aquaporins (AQPs) are channel proteins regulating water and small solute transport across cell membranes.
  • Thirteen AQP isoforms exist in mammals, with several potentially expressed in platelets.
  • Platelet AQPs play a role in osmotic swelling, calcium influx, and membrane dynamics.

Purpose of the Study:

  • To review the role of aquaporins in platelet function, including secretion, aggregation, and procoagulation.
  • To discuss the challenges and prospects of targeting AQPs for antithrombotic therapies.
  • To explore AQP-mediated mechanisms in arterial and venous thrombosis.

Main Methods:

  • Review of existing literature on aquaporins and platelet biology.
  • Analysis of studies investigating AQP function in platelet procoagulant activity.
  • Examination of animal models of thrombosis related to AQP function.

Main Results:

  • AQP1-mediated osmotic swelling is crucial for platelet phosphatidylserine exposure and microvesiculation.
  • AQP1 deletion reduces platelet procoagulant activity and arterial thrombosis in vivo.
  • Platelet AQPs are implicated in both arterial and venous thrombosis, independent of granule secretion.

Conclusions:

  • Platelet AQPs are promising targets for novel anti-procoagulant antithrombotics.
  • Targeting AQPs presents challenges due to their structure but is supported by compelling thrombosis data.
  • Further research into AQP-targeted antithrombotics is warranted for both arterial and venous thrombosis.